World Vaccine Congress Barcelona 16 to 19 October, 2023.
World Vaccine and Immunotherapy Congress West Coast, Santa Clara, CA 27 to 30 November, 2023.
Our Team
Orlance, Inc., headquartered in Seattle, WA, is developing its MACH-1® platform to deliver nucleic acid vaccines and related therapies without cold chain restrictions. Leveraging $9.6M in NIH SBIR funding, Orlance has developed the MACH-1 platform to intradermally deliver stable, powdered vaccines in a needle-free manner that minimizes dose size, eliminates cold chain requirements, and is poised to increase access and compliance. The company’s lead assets are at Pre-IND stage and poised for Phase 1 readiness in 2023.
KRIS AALTO, BS
CEO 25 years of bioengineering, innovation development, regulatory and clinical affairs, product launch, VC and executive experience.
DEB FULLER, PHD
CTO Co-inventor of MACH-1 technology, formerly at PowderJect, UW Professor, the lab focuses on NA vaccines for multiple pathogens.
KEN BAGLEY, PHD
Director R&D 15 years in NA vaccine field, developed genetic adjuvant platform at Profectus Biosciences, Inc.
HANNAH FRIZZELL, PHD
Manager Preclinical Development Bioengineer, Immunology, and nano delivery system experience.
AMANDA WOODCOCK, BS
Mechanical Engineer Medical device design and system integration lead.
LYUDA LEBEDINSKI, BS
Senior Administrative and Financial Manager Experienced biomedical research finance, federal funding and management professional.
ATHARVA BHALERAO, BS
Research Scientist and Analyst Preclinical program laboratory and business development support.